Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 |
| clinicaltrials |
| NCT05578378 | Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL | unknown | Phase 2 / Phase 3 | 32 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03697707 | Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia(ADVANCE-II) | unknown | Phase 2 | 20 | MendusINDUSTRY | 5 | Oct 10, 2022 | clinicaltrials |
| NCT03624270 | Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia | unknown | Phase 2 | 60 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT04689815 | Oral Arsenic Trioxide for NPM1-mutated AML | unknown | Phase 2 | 50 | The University of Hong KongOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05559450 | Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL | unknown | Phase 2 | 80 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT04248595 | Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML | unknown | Phase 2 | 100 | Ge ZhengOTHER | 1 | Sep 8, 2022 | clinicaltrials |
| NCT05466175 | A Study of Olverembatinib in the Treatment of Ph+ ALL | unknown | Phase 2 | 55 | Chen SuningOTHER | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05513131 | Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT05488132 | Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) | unknown | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT03564470 | Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL | unknown | Phase 2 / Phase 3 | 120 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT04632316 | A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 33 | Glycostem Therapeutics BVINDUSTRY | 5 | Jun 21, 2022 | clinicaltrials |
| NCT05404516 | Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML | unknown | Phase 2 | 88 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT05362942 | Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia | unknown | Phase 2 | 52 | Beijing 302 HospitalOTHER | 0 | May 5, 2022 | clinicaltrials |
| NCT05330364 | Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia | unknown | Phase 2 | 31 | Ge ZhengOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02752243 | CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. | unknown | Phase 1 / Phase 2 | 32 | Peter BaderOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT04764513 | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | unknown | Phase 1 / Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT04867928 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia | unknown | Phase 2 | 35 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02776605 | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia(PONALFIL) | unknown | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT05175508 | Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS | unknown | Phase 2 / Phase 3 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 3, 2022 | clinicaltrials |
| NCT05023707 | Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT04752527 | Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features | unknown | Phase 2 | 42 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT04674345 | Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia | unknown | Phase 2 / Phase 3 | 346 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT05100303 | A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT04846439 | Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05066958 | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT | unknown | Phase 1 / Phase 2 | 20 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT05054465 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL(ITALLI001) | unknown | Phase 1 / Phase 2 | 48 | Israeli Medical AssociationOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT04906031 | Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations | unknown | Phase 2 | 5 | First Affiliated Hospital of Jinan UniversityOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT04069208 | IA14 Induction in Young Acute Myeloid Leukemia | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT01894477 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | unknown | Phase 2 | 102 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 3, 2021 | clinicaltrials |
| NCT04762485 | Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04904237 | Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML. | unknown | Phase 2 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT01498016 | Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia | unknown | Phase 2 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04884984 | Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML) | unknown | Phase 1 / Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04334993 | Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study | unknown | Phase 2 | 110 | Israeli Medical AssociationOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT03080766 | The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype | unknown | Phase 2 | 20 | The University of Hong KongOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04747002 | Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients. | unknown | Phase 2 | 100 | Osaka UniversityOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04747093 | Induced-T Cell Like NK Cells for B Cell Malignancies | unknown | Phase 1 / Phase 2 | 12 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04740203 | Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL | unknown | Phase 1 / Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03265106 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 20 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04723901 | Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia(CAR-T) | unknown | Phase 1 / Phase 2 | 20 | Shenzhen University General HospitalOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT04688983 | Study in Adult Ph-positive ALL(EWALL-Ph-03) | unknown | Phase 2 | 180 | Cardiff UniversityOTHER | 0 | Dec 30, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04254640 | Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML | unknown | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 26, 2022source: clinicaltrials